HOME >> BIOLOGY >> NEWS
Research suggests new avenue for stopping, preventing colon cancer

NASHVILLE, Tenn. Researchers at the Vanderbilt-Ingram Cancer Center (VICC) have provided the first evidence that blocking a cellular receptor can inhibit the development of pre-cancerous colon polyps in mice.

The research suggests a new avenue for stopping or preventing colon cancer, which kills more than 50,000 Americans each year, said the paper's senior author, Raymond N. DuBois, M.D., Ph.D., Hortense B. Ingram Professor of Molecular Oncology and the VICC's associate director for Cancer Prevention and Control.

The receptor, called PPARdelta, plays an important role in development, wound healing and fat metabolism. In the current issue of the journal Cancer Cell, the scientists reported that they could inhibit polyp development in mice by "knocking out" the PPARdelta gene. PPAR stands for peroxisome proliferator-activated receptor, a family of three "transcription factors" that serve as on-off switches for a wide variety of genes.

DuBois is internationally known for his pioneering studies linking the development of colorectal cancer to the cyclooxygenase-2 (COX-2) enzyme. COX-2 is a major target for drugs that relieve the pain and inflammation of arthritis, but COX-2 gene expression is also elevated in a variety of malignancies including colorectal tumors.

COX-2 generates several potent, hormone-like substances called prostaglandins that play a role in a wide variety of physiological functions. One of them, prostaglandin E2 (PGE2), has been specifically linked to the development of colon polyps. The current study tested the effect of PGE2 in mice with the mutation that made them susceptible to polyps. Administration of the prostaglandin dramatically increased the number of intestinal polyps.

The animals were then crossed with mice without the PPARdelta gene. This generated animals with the propensity to develop colon polyps but lacking PPARdelta. When PGE2 was given to these mice, "we didn't seen any increase in polyps," DuBois said
'"/>

Contact: Cynthia Floyd Manley
cynthia.manley@vanderbilt.edu
615-936-5711
Vanderbilt University Medical Center
20-Sep-2004


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
4. Researchers identify protein promoting vascular tumor growth
5. Researchers devise potent new tools to curb ivory poaching
6. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
7. Researchers ID chlorophyll-regulating gene
8. Environmental issues center of Inland Northwest Research Alliance 4th Annual Symposium
9. Researchers develop fast track way to discover how cells are regulated
10. Research on carbohydrate metabolism receives historical recognition
11. Researchers identify distinctive signature for metastatic prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2019)... , ... April 04, 2019 , ... ... with integrated linear encoders providing 0.05 microns and 0.005 microns resolution, respectively. The ... and drive variations are available, from fast DC-servo motors with linear encoders and ...
(Date:4/4/2019)... ... April 02, 2019 , ... The live session ... into the connectivity between product risk management (ISO 14971) and the clinical risk ... process. , With increasing global regulation and reimbursement challenges faced by medical device ...
(Date:4/1/2019)... (PRWEB) , ... April 01, 2019 , ... ... and System for Characterizing Skin Related Conditions” by the US Patent and Trademark ... The patent is an invention by uBiome collaborators Dr. Zachary Apte, Dr. ...
Breaking Biology News(10 mins):
(Date:4/9/2019)... ... April 09, 2019 , ... Sonny Bar Lisa, or Sonny ... for approximately two months. After a series of diagnostics, an MRI was performed ... owner, Alison, researched the injury and found that VetStem Regenerative Cell Therapy ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global ... $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). ... Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin ...
(Date:4/4/2019)... (PRWEB) , ... April 03, 2019 , ... ... together through intimate off-the-record collaboration and dialogue, today announces its Boston CEO conference ... offers insights into the industry’s challenges and opportunities with high-level panels and discussions ...
(Date:3/27/2019)... ... March 27, 2019 , ... In honor of National Nutrition Month, ... importance of healthy meals and good nutrition. This month, Chef Jodi Abel appeared ... chef. , The first segment addressed the nutritional value of USDA’s MyPlate, ...
Breaking Biology Technology:
Cached News: